2019 Annual Meeting | C86 - Neuromyelitis Optica Spectrum Disorders

Date Monday 05/06/19

Time 07:00 AM - 09:00 AM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Dean M. Wingerchuk, MD, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants should be able to understand the clinical, neuroimaging, laboratory, and pathologic characteristics of NMOSD; compare the utility of AQP4-IgG assay methods; recognize clinical characteristics associated with MOG-IgG; be able to discuss elements of the newly revised NMOSD diagnostic criteria; and describe approaches to prevention and treatment of acute NMOSD attacks.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:45 AM EDT	Speaker	NMOSD: Pathogenesis and Clinical Diagnosis Brian G. Weinshenker, MD, FAAN
07:45 AM - 08:30 AM EDT	Speaker	NMOSD: Treatment Options and Strategies Dean M. Wingerchuk, MD, FAAN
08:30 AM - 09:00 AM EDT	Speaker	NMOSD: Case Vignettes

Faculty Disclosures
Dean M. Wingerchuk, MD, FAAN	Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TTY Biopharm. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Biopharm. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.
Brian G. Weinshenker, MD, FAAN	Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��